Literature DB >> 26807360

Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients.

Romaric Loffroy1, Béatrice Terriat1, Valérie Jooste1, Isabelle Robin1, Marie-Claude Brindisi1, Patrick Hillon1, Bruno Vergès1, Jean-Pierre Cercueil1, Jean-Michel Petit1.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is independently associated with atherosclerosis in nondiabetic individuals. In type 2 diabetic patients, the link between fatty liver and atherosclerosis is less clear. Here, we assessed whether liver fat content evaluated using (1)H-magnetic resonance spectroscopy ((1)H-MRS) was independently associated with prevalent carotid plaque as a marker of atherosclerosis in type 2 diabetic patients.
METHODS: One hundred and forty-four prospectively enrolled patients with type 2 diabetes underwent liver fat content measurement using (1)H-MRS and carotid plaque assessment using ultrasound. Multiple logistic regressions were used to identify factors associated with carotid plaque.
RESULTS: Mean ± SD liver fat content was 9.86±8.12%. Carotid plaque prevalence was 52.1% (75/144). Patients without plaque were younger (P=0.006) and had a smaller visceral fat area (P=0.015), lower reported prevalence of previous cardiovascular events or current statin therapy (P=0.002), and higher liver fat content than those with plaque (P=0.009). By multivariable logistic regression, increased liver fat content independently predicted the absence of carotid plaque [odds ratios (ORs), 0.94; 95% confidence intervals (CIs), 0.89-0.99; P=0.017].
CONCLUSIONS: Liver fat content measured by (1)H-MRS is higher in type 2 diabetic patients without carotid plaque compared to those with plaque. This study suggests that increased liver fat content could be associated with a relative protection against carotid atherosclerosis in patients with type 2 diabetes mellitus.

Entities:  

Keywords:  Hepatic steatosis; atherosclerosis; carotid plaque; nonalcoholic fatty liver disease (NAFLD); type 2 diabetes

Year:  2015        PMID: 26807360      PMCID: PMC4700244          DOI: 10.3978/j.issn.2223-4292.2015.12.03

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  31 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Use of monitoring software to improve the measurement of carotid wall thickness by B-mode imaging.

Authors:  P J Touboul; P Prati; P Y Scarabin; V Adrai; E Thibout; P Ducimetière
Journal:  J Hypertens Suppl       Date:  1992-07

3.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

Authors:  Nicola Villanova; Simona Moscatiello; Stefano Ramilli; Elisabetta Bugianesi; Donatella Magalotti; Ester Vanni; Marco Zoli; Giulio Marchesini
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

Review 4.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease.

Authors:  Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2004-08       Impact factor: 6.126

5.  Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass.

Authors:  Antonio Picardi; Umberto Vespasiani-Gentilucci
Journal:  Am J Gastroenterol       Date:  2008-10-01       Impact factor: 10.864

6.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

7.  Carotid lesions in outpatients with nonalcoholic fatty liver disease.

Authors:  Stefano Ramilli; Stefano Pretolani; Antonio Muscari; Barbara Pacelli; Vincenzo Arienti
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

8.  Nonalcoholic fatty liver disease in patients with type 2 diabetes.

Authors:  Zobair M Younossi; Terry Gramlich; Christi A Matteoni; Navdeep Boparai; Arthur J McCullough
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

9.  Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients.

Authors:  G Targher; L Bertolini; R Padovani; F Poli; L Scala; L Zenari; G Zoppini; G Falezza
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

Review 10.  Fatty liver: a novel component of the metabolic syndrome.

Authors:  Anna Kotronen; Hannele Yki-Järvinen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-09       Impact factor: 8.311

View more
  4 in total

1.  Quantitative evaluation of bone marrow fat content and unsaturated fatty index in young male soccer players using proton magnetic resonance spectroscopy (1H-MRS): a preliminary study.

Authors:  Jian Wang; Peiwei Yi; Yaobin Huang; Qinqin Yu; Yingjie Mei; Jialing Chen; Yanqiu Feng; Xiaodong Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-10

2.  Nonalcoholic Fatty Liver Disease in Hispanic Youth With Dysglycemia: Risk for Subclinical Atherosclerosis?

Authors:  Fida Bacha; Anca Tomsa; Sara K Bartz; Sarah E Barlow; Zili David Chu; Ramkumar Krishnamurthy; Rajesh Krishnamurthy; E O'Brian Smith
Journal:  J Endocr Soc       Date:  2017-06-27

3.  Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects.

Authors:  Anders Gummesson; Ulf Strömberg; Caroline Schmidt; Joel Kullberg; Oskar Angerås; Stefan Lindgren; Ola Hjelmgren; Kjell Torén; Annika Rosengren; Björn Fagerberg; John Brandberg; Göran Bergström
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

4.  Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis.

Authors:  Abid Rasool; Waseem Dar; Muzamil Latief; Imtiyaz Dar; Najeebullah Sofi; Mushtaq Ahmad Khan
Journal:  Brain Circ       Date:  2017-03-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.